Providing due diligence in neurology
Challenge
A venture capital investor needed an assessment of the technical, regulatory and market risks in a neuroscience specialty pharma company developing a range of products through the 505 (b)(2) regulatory pathway.
Solution
We gave an assessment of the likely investor returns under two possible scenarios, and advised on the most likely exit triggers/timings. The client expressed a high level of satisfaction with our work.
Related Case Studies
Explore similar engagements and see how we've helped other clients achieve their goals.
Due Diligence
Pre-Due Diligence Assessment of First-in-Class Allergy Therapeutic
Challenge: A pharmaceutical company seeking new assets requested a pre-due diligence assessment of a European biotech developing a first-in-class compound for treating allergic...
Due Diligence
Strategic Partnership Assessment of Autoimmune Drug Development Program
Challenge: A pharmaceutical client asked Alacrita to assess a early-stage biotech company developing an orally-available agent for treating various autoimmune conditions. The...
Due Diligence
Pre-Due Diligence Assessment of a Women's Health Biotech Partnership
Challenge: A pharmaceutical company was actively searching for strategic partnering opportunities to expand its pipeline and had commissioned Alacrita to conduct a comprehensive...
Due Diligence
Due Diligence of an Academic Adenovirus Gene-Therapy Program
Challenge: A pharmaceutical company with an established gene-therapy franchise wanted to expand its oncology pipeline through external licensing. Among several options, the deal...
Interested in Learning More?
Contact us to discuss how we can support your project with similar expertise.